Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT)
An Open-label, Multi-centric, Phase I, Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
Sponsor: Centre Georges Francois Leclerc
A PHASE1 clinical study on Metastatic Bladder Cancer and Metastatic Head and Neck Cancer, this trial is ongoing. The trial is conducted by Centre Georges Francois Leclerc and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Dec 2025 — Present [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Sep 2024 — Dec 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2022 — Nov 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Georges Francois Leclerc
For direct contact, visit the study record on ClinicalTrials.gov .